WeissLaw LLP: The Auspex Pharmaceuticals, Inc. Acquisition by Teva Pharmaceutical Industries Is the Subject of a Legal Investigation

NEW YORK, April 3, 2015 /PRNewswire/ -- The fairness of the proposed acquisition of Auspex Pharmaceuticals Inc. ("ASPX" or the "Company") by Teva Pharmaceutical Industries ("Teva") is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm.  The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of ASPX for agreeing to sell the Company to Teva.  On March 30, 2015, the Company announced a definitive agreement for Teva to acquire ASPX in a transaction valued at approximately $3.5 billion.  Under the terms of the agreement, ASPX shareholders will receive $101.00 in cash for each ASPX share they own. 

WeissLaw is investigating whether ASPX's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a price target of $105.00 per share, or $4.00 above the offer price. 

Given these facts, WeissLaw is investigating whether ASPX's Board acted in the best interests of ASPX's public shareholders by actively shopping the Company to maximize shareholder value prior to entering into the agreement with Teva.  If you own ASPX shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin or Kelly Keenan by telephone at (888) 593-4771 or by email at [email protected].  

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected] or fill out the form on our website, http://www.weisslawllp.com/contact/report_fraud/.

Attorney Advertising.  Past results do not guarantee a similar outcome.

WeissLaw LLP
Joshua Rubin
Kelly Keenan
1500 Broadway, 16th Floor
New York, NY  10036
T:  212.682.3025
F:  212.682.3010
www.weisslawllp.com
[email protected]

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/weisslaw-llp-the-auspex-pharmaceuticals-inc-acquisition-by-teva-pharmaceutical-industries-is-the-subject-of-a-legal-investigation-300060863.html

SOURCE WeissLaw LLP

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.